Accelerated growth of syngeneic tumors in mice treated with methylcholanthrene
β Scribed by Patsy H. Lill; J. Milburn Jessup; Margaret L. Kripke
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- French
- Weight
- 435 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BALB/c and C3Hβ mice were given a single injection of methylcholanthrene (MCA) and were tested at various times thereafter for immunologic reactivity and resistance to syngeneic tumor challenge. MCA treatment did not affect the rejection of Hβ2βincompatible tumor allografts, the rejection of Hβ2βcompatible skin allografts, or the induction of delayed hypersensitivity to DNCB as measured by footpad challenge. In contrast, mice treated with MCA exhibited an increased susceptibility to challenge with several syngeneic ultravioletβinduced and MCAβinduced fibrosarcomas. These studies demonstrate that in the autochthonous host the measurement of host immune status by in vivo cellβmediated immune responses to exogenous antigens does not necessarily predict the host response to tumor growth.
π SIMILAR VOLUMES
Facilitated tumor growth was observed in syngeneic animals after the subcutaneous inoculation of these animals with normal syngeneic spleen cells a n d tumor cells previously mixed in vitro. T u m o r incidence, latency, a n d growth rate appear quantitatively directly related to the ratio of spleen
## Abstract The growth of a transplantable tumor (KMTβ17) in syngeneic Wistar King Aptekman/Mk (WKA) rats was inhibited by preimmunization with allogeneic normal cells from Donryu strain rats. The phenomenon is referred to as allogeneic cell immunity. A slight inhibition was observed in rats immuni
We have studied the anti-tumor effects of human recombinant IL2, alone or in association with LAKcells, in mice transplanted subcutaneously (s.c.) with the following syngeneic tumors: highly metastatic Friend leukemia cells (FLC), nonmetastatic FLC, lymphoma RBL-5 cells and HeJ16 fibrosarcoma cells.